work construct comprehensive singlecell atlas immune cell cdlns eau mouse various time point day 0 7 14 21 depict alteration immune cell composition gene expression disease progress particular singlecell data implicate pim1 preferentially upregulated th17 cell th1 cell treg cell plasma cell pc eau repress pim1 reduce imbalance th17treg cell pc differentiation moreover inhibit pim1 reduce th17 pathogenicity furthermore study verify upregulation pim1 cd4 cell pc human uveitis vogtkoyanagiharada disease vkh inhibit pim1 also suppress proliferation cd4 cell b cell patient vkh data suggest target pim1 kinase may potential therapy vkh investigate dynamic change immune cellular response eau establish eau model inject mouse commonly use uveitogenic retinal protein irbp along complete freund 's adjuvant pertussis toxin exclude simple immunization manipulationrelated effect induce reagent mouse control group inject complete freund 's adjuvant pertussis toxin fig 1a mouse immunize irbp eau develop day 7 symptom worsen day 14 21 day 7 14 21 eau group mouse sacrifice day 0 injection define day 0 group day 7 14 21 control group day 7 14 21 control group exhibit eau symptom supplementary fig 1a b. singlecell suspension obtain mouse cdlns group translate barcoded single cell rna sequence scrnaseq library subsequent research fig 1a eight major immune cell type include b cell cell natural killer nk cell monocyte mono macrophage macro classical dendritic cell cdc plasmacytoid dendritic cell pdc neutrophil neu identify cdlns accord classical lineage marker fig 1b c supplementary fig 1c d. cell b cell dominant among cdln cell myeloid cell form relatively small ratio fig 1d cell proportion show similar variation trend eau control group fig 1d capture dynamic global gene signature eau conduct differentially express gene deg analysis control group day 0 group eau control group correspond day control group show upregulated inflammatory s100a8 s100a9 immunoglobulin productionrelated ighg1 ighg2b gene compare day 0 group supplementary fig 1e compare control group eau group show upregulated gene relate cell activation fo jun jund cd69 il17 signal cebpd junb immunoglobulin production ighg1 ighg2b different day fig 1e subsequent go analysis show pathway relate lymphocyte activation immune response immunoglobulin production enrich control group compare day 0 group pathway enrich eau group compare correspond control group fig 1f moreover il17 signal pathway uniquely enrich eau group fig 1f investigate gene exclusively upregulated eau group remove upregulated degs identify control group vs. day 0 group comparison construct venn diagram fig 1g ten gene exclusively upregulated eau group two consecutive time point fig 1g h. among jun jund fo dusp1 ppp1r15a relate inflammation cell activation fig 1h junb cebpb relate il17 signal pathway fig 1h stk17b tmem243 pim1 associate tumor fig 1h intriguingly pim1 reportedly involve tumor immunology abnormal upregulation molecule eau arouse interest next explore dynamic transcriptional change eight major immune cell type eau control group neutrophil monocyte show largest number degs day 14 compare day 0 supplementary fig 1f eau group two immune cell type exhibit highest number degs day 7 compare control group supplementary fig 1f day 14 21 b cell cell higher number degs myeloid cell eau group supplementary fig 1f conduct go analysis annotate biological significance degs cell control group degs enrich pathway relate inflammation cytokine signal compare day 0 group whereas il17 signal leukocyte differentiation cell activation pathway enrich eau group supplementary fig 2a b cell pathway relate immunoglobulin production b cell activation enrich control group compare day 0 group pathway enrich eau group compare correspond control group supplementary fig 2b transcriptional change eau group include enrich pathway annotate tnf signal pathway nk cell interleukin1 beta production monocyte adaptive immune system macrophage antigen process presentation dc well neutrophil degranulation neutrophil supplementary fig 2ch generally enrichment pathway evident day 7 14 compare day 21 eau group supplementary fig 2ah might suggest acute inflammation first 2 week find show dynamic change proportion transcription major immune cell type eau compare control group represent condition affect immunization manipulationrelated effect consider vital function cell eau pathogenesis cell reclustered eight subset include na07ve cd4 ncd4 cell na07ve cd8 ncd8 cell cytotoxic cell ctl treg cell follicular helper tfh cell th17 cell th1 cell proliferative prot cell fig 2ac eau proportion th17 th1 cell two effector cell subset eau increase first 2 week decrease fig 2d prot cell also show similar tendency peak day 7 fig 2d next evaluate expression pim1 cell subset pim1 noticeably upregulated th17 cell th1 cell treg cell fig 2e among th17 cell treg cell core regulator pathogenesis uveitis suggest pim1 may involve th17treg cell imbalance uveitis investigate dynamic change cell subset transcriptome conduct go analysis degs cell subset day 7 main enrich pathway cell subset annotate cellular response stress stimulus supplementary fig 3a eau several pathway uniquely enrich day 7 compare control group tnf signal pathway ctls na07ve cd4 cell tfh cell leukocyte differentiation pathway na07ve cd4 cell il17 signal pathway na07ve cd4 cell th17 cell supplementary fig 3b day 14 uniquely enrich pathway eau remain evident pathway annotate cellular response stress stimulus enrich cell subset compare control group fig 2f g. day 21 electron transport chain atp metabolic process pathway widely enrich cell subset eau supplementary fig 3c d. collectively evident upregulation pim1 expression th17 cell treg cell indicate potential involvement pim1 eau pathogenesis additionally go analysis cell subset show enrich pathway different cell subset time point analysis identify upregulation pim1 eau transcriptional level pim1 member pim kinase family actively involve cell proliferation survival apoptosis many disease evaluate involvement pim1 eau conduct immunostaining cdlns pim1 verify enhance expression eau protein level fig 3a next smi4a pim1 inhibitor administer eau mouse eau symptom significantly reduce mouse treat inhibitor determine fundus examination histopathological analysis fig 3b c supplementary fig 3e moreover flow cytometry cdln cell show smi4a treatment reduce proportion th1 th17 cell enhance proportion treg cell compare vehicletreated group fig 3df reduce proportion pim1 cell among th1 cell th17 cell treg cell tfh cell smi4a treatment also verify flow cytometry fig 3gi supplementary fig 3f g. furthermore treat eau mouse another pim1 highly selective inhibitor quercetagetin quercetagetin also effectively alleviate eau symptom supplementary fig 3h i. result indicate pim1 may exacerbate eau via regulation cd4 cell subset explore function pim1 eau vitro experiment conduct use smi4a smi4a 20 μm affect cell viability effectively repress proliferation cd4 cell supplementary fig 4ad therefore choose dose follow experiment cdln cell isolate mouse eau group culture irbp 72 h presence absence smi4a note proportion th1 th17 cell decrease presence smi4a whereas treg cell increase fig 4ac meanwhile transfer smi4atreated nontreated cd4 cell mouse observe pathogenicity cd4 cell dampen smi4a treatment fig 4d e. similar experiment conduct use pim1targeting short hairpin rna pim1 shrna pim1 shrna induce similar change proportion cd4 cell subset supplementary fig 5ad prevent cd4 cell induce eau adoptive transfer experiment fig 4f g. result indicate pim1 indispensable pathogenicity cd4 cell eau balance th17 cell treg cell core regulator uveitis pathogenesis thus explore regulatory function pim1 th17treg cell balance protein kinase b akt regulate pim1 addition aktforkhead box protein o1 foxo1 pathway show regulate balance th17 cell treg cell involve several disease multiple sclerosis aktfoxo1 pathway foxo1 locate nucleus enhance treg cell function via maintain expression foxp3 repress differentiation th17 cell inhibit expression rorγ phosphorylated akt directly phosphorylate foxo1 induce foxo1 leave nucleus relocate cytosol lose regulatory function th17 cell treg cell explore activity pim1aktfoxo1 pathway eau pathogenesis isolate cdln cell eau mouse treat cell irbp irbp plus smi4a assess level pim1 pakt pfoxo1 flow cytometry demonstrate irbp treatment increase proportion pim1 cell stimulate phosphorylation akt foxo1 total cd4 cell irbpassociated effect reverse smi4a treatment fig 4hj result indicate abnormal pim1aktfoxo1 pathway eau may contribute th17 treg cell imbalance uveitis may ameliorate pim1inhibiting within cd4 cell subset th17 cell know critical pathogenic cell type eau transfer autoreactive th17 cell induce eau development therefore isolate cd4 ccr6 cxcr3 cell th17 cell eau mouse pim1 shrna treatment abrogate capacity th17 cell transfer disease na07ve mouse supplementary fig 5e indicate pim1 essential pathogenicity th17 cell therefore disease summary inhibit pim1 identify pim1 regulate balance th17 cell treg cell may result downstream aktfoxo1 signal additionally pim1 indispensable pathogenicity th17 cell eau although function b cell eau le certain cell increase evidence support pathogenic function autoimmune disease multiple sclerosis thus reclustered b cell identify three b cell subtypes include germinal center b cell gc na07ve b cell pc fig 5a supplementary fig 6a b. proportion pc show trend increase decrease peak day 14 fig 5b c. investigate dynamic change transcriptome b cell subset eau conduct go analysis degs b cell subset b cell subset show various pathway exclusively enrich eau different time point example protein fold export pathway enrich plasma cell day 7 leukocyte differentiation adaptive immune response pathway enrich na07ve b cell day 14 lymphocyte activation b cell differentiation pathway na07ve b cell atp metabolic process pathway gc enrich day 21 supplementary fig 6c subsequently explore antibody production critical process many autoimmune disease eau obtain isotype information immunoglobulin bcell receptor bcr sequence extract b cell transcriptomes analyze show fig 5d percentage ighg igha increase eau implicate isotype switch immunoglobulin igmigd iggiga result bcell activation eau elisa perform evaluate serum level antiirbp igg antibody isotypes igg1 igg2a igg2b igg3 igg2c day 0 group eau group different time point fig 5e supplementary fig 6d serum level antiirbp total igg isotypes igg1 igg2b increase eau group day 7 reach maximum level day 14 decrease fig 5e serum level igg2a igg3 differ significantly time point supplementary fig 6d eae animal model show many similarity pathogenic mechanism eau b cell reportedly dual function depend disease stage anticd20 antibodymediated b cell depletion eae induction exacerbate disease symptom b cell depletion eae disease progression suppress disease symptom explore function b cell eau administrate anticd20 antibody deplete b cell 7 day immunization day 7 eau development 7 day immunization day 7 fig 5f g. flow cytometry validate dramatically decrease b cell proportion two anticd20 antibody treatment group supplementary fig 6e deplete b cell induction eau accelerate disease initiation eau develop day 5 fig 5g however deplete b cell eau development ameliorate eau symptom fig 5g result indicate b cell mainly protective effect initiation stage eau exert pathogenic function eau consider enhance antiirbp antibody eau speculate pc might also contribute eau pathogenesis pc think particularly sensitive bortezomib bz proteasome inhibitor due high rate antibody production current study bz administer eau mouse twice week 2 week treatment bz eau symptom ameliorate show lower clinical pathological score supplementary fig 7ac percentage pc within b cell serum level antiirbp igg isotypes igg1 igg2b eau mouse reduce bz treatment supplementary fig 7d e. bz also inhibit pc differentiation vitro experiment supplementary fig 7f also evaluate influence bz administration pim1aktfoxo1 pathway total cd4 cell bz influence expression pim1 phosphorylation akt inhibit phosphorylation foxo1 supplementary fig 7gi result indicate pc depletion bz might contribute amelioration eau evaluate expression function pim1 b cell subset pim1 mainly express pc scrnaseq data fig 5h i. smi4a treatment reduce proportion pc serum level antiirbp igg isotypes igg1 igg2b eau mouse show flow cytometry elisa fig 5j l. proportion pim1 cell pc gc reduce smi4a fig 5k supplementary fig 8a b. also investigate function pim1 differentiation pc vitro sort b cell culture 5 day cd40l igm fab 2 il4 il5 without smi4a smi4a treatment decrease proportion pc b220 cd138 fig 5m similarly pim1 shrna inhibit pc differentiation supplementary fig 8c d. evaluate effect smi4a aktfoxo1 pathway plasma cell smi4a reduce phosphorylation akt significantly influence expression pfoxo1 plasma cell supplementary fig 8e f. result indicate pim1 may engage pc differentiation effect may also contribute eau pathogenesis vkh one common type human uveitis asia characterize type bilateral uveitis frequently associate neurological meningeal auditory integumentary manifestation investigate whether upregulation pim1 expression conserve human uveitis generate scrnaseq data peripheral blood mononuclear cell pbmc obtain six patient vkh six healthy control hc five immune cell type recognize base classical lineage marker supplementary fig 9ad conduct deg go analysis identify transcriptional change human vkh supplementary fig 9e f. total pbmcs degs relate cell activation cd69 il17 signal junb inflammation s100a8 s100a9 pim1 upregulated patient vkh compare hcs supplementary fig 9e correspondingly degs patient vkh enrich pathway relate chronic inflammatory response il17 signal cell activation compare hcs supplementary fig 9f cell cd69 junb pim1 upregulated cell activation pathway enrich patient vkh supplementary fig 10a b. additionally immunoglobulinrelated gene ighg1 igha1 pathway upregulated b cell patient vkh supplementary fig 10c d. transcriptional change patient vkh analogous observe eau mouse next reclustered cell identify seven know cell subset human pbmcs include cd4 na07ve cd4 na07ve cell cd4 central memory cd4 tcm cell cd4 effector memory cd4 tem cell cd4 treg cell cd8 na07ve cd8 na07ve cell cd8 tem cell cd8 cytotoxic cell cd8 ctl fig 6a supplementary fig 10e f. b cell also reclustered three b cell subset incorporate na07ve b cell memory b cell plasma b cell pc fig 6b supplementary fig 10g h. cd4 cell subset pc show upregulated pim1 expression patient vkh compare hcs fig 6ce protein level cd4 cell pc exhibit increase pim1 expression patient vkh fig 6f g supplementary fig 11a b. smi4a 20 μm influence cell viability effectively repress cell proliferation supplementary fig 11cf therefore choose dose follow experiment cd4 cell b cell treat smi4a show decrease expansion compare untreated group fig 6h i. similarly pim1 shrna inhibit proliferation cd4 cell b cell supplementary fig 12af additionally find addition smi4a pim1 shrna treatment slightly inhibit proliferation cd4 cell supplementary fig 12b c. thus upregulation pim1 expression therapeutic function pim1 inhibitor may extend vkh explore whether upregulation pim1 unique uveitis download scrnaseq data patient m previous study analyze pim1 expression dataset supplementary fig 13af pim1 expression pbmcs patient m show similar alteration patient vkh disease pim1 expression upregulated nearly cell subset supplementary fig 13g i. pim1 expression also upregulated pc supplementary fig 13h i. therefore increase pim1 expression potential therapeutic value target pim1 may limit uveitis may also apply cns autoimmune disease